Xoc Pharmaceuticals, Inc., a Los Gatos, Calif.-based early-stage biopharmaceutical company focused on the development of innovative therapeutics for diseases of the central nervous system (CNS), closed a tranched $30m Series A financing.
The round was led by New Enterprise Associates (NEA). In conjunction with the funding, NEA Partner Frank Torti will join the Xoc Board of Directors.
The funding will enable the company to complete pre-clinical testing and take its two lead compounds into the clinic.
Led by Scott W. Borland, President and CEO, Xoc Pharmaceuticals develops novel oral therapies for the prevention of migraine and the maintenance of Parkinson’s disease. The company leverages information on existing compounds with established pharmacological and clinical history and utilizes its receptor characterization proprietary design and development process to create novel compounds for improved efficacy and/or reduced side effects.